SciPi 353: Grouping of Per- and Polyfluoroalkyl Substances (PFAS) for Human Health Risk Assessment
Based on a consideration of feasibilityt, please rate the following grouping strategies on a scale of 1-10 (1=lowest, 10=highest)
Results
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | Total | |
---|---|---|---|---|---|---|---|---|---|---|---|
Production/Use | 0.00% 0 | 10.00% 1 | 10.00% 1 | 20.00% 2 | 0.00% 0 | 0.00% 0 | 0.00% 0 | 30.00% 3 | 10.00% 1 | 20.00% 2 | 10 |
Potential exposure route | 0.00% 0 | 10.00% 1 | 10.00% 1 | 10.00% 1 | 10.00% 1 | 10.00% 1 | 30.00% 3 | 10.00% 1 | 0.00% 0 | 10.00% 1 | 10 |
Biological half-life | 0.00% 0 | 10.00% 1 | 10.00% 1 | 10.00% 1 | 20.00% 2 | 30.00% 3 | 0.00% 0 | 10.00% 1 | 0.00% 0 | 10.00% 1 | 10 |
Physical-chemical properties | 0.00% 0 | 0.00% 0 | 0.00% 0 | 0.00% 0 | 20.00% 2 | 20.00% 2 | 0.00% 0 | 40.00% 4 | 10.00% 1 | 10.00% 1 | 10 |
Carbon chain length/chemical structure | 0.00% 0 | 0.00% 0 | 10.00% 1 | 0.00% 0 | 10.00% 1 | 0.00% 0 | 0.00% 0 | 20.00% 2 | 20.00% 2 | 40.00% 4 | 10 |
Toxicological endpoints | 10.00% 1 | 0.00% 0 | 40.00% 4 | 0.00% 0 | 20.00% 2 | 20.00% 2 | 0.00% 0 | 0.00% 0 | 0.00% 0 | 10.00% 1 | 10 |
Mode of action | 20.00% 2 | 30.00% 3 | 10.00% 1 | 0.00% 0 | 10.00% 1 | 10.00% 1 | 0.00% 0 | 10.00% 1 | 0.00% 0 | 10.00% 1 | 10 |
Other (please explain below) | 0.00% 0 | 0.00% 0 | 0.00% 0 | 0.00% 0 | 0.00% 0 | 0.00% 0 | 0.00% 0 | 0.00% 0 | 50.00% 1 | 50.00% 1 | 2 |
Answer Explanations
- Expert 10
Grouped by: 1 2 3 4 5 6 7 8 9 10 Production/Use 0 0 1 0 0 0 0 0 0 0 Potential exposure route 0 0 1 0 0 0 0 0 0 0 Biological half-life 0 0 0 0 1 0 0 0 0 0 Physical-chemical properties 0 0 0 0 0 1 0 0 0 0 Carbon chain length/chemical structure 0 0 0 0 0 0 0 1 0 0 Toxicological endpoints 1 0 0 0 0 0 0 0 0 0 Mode of action 1 0 0 0 0 0 0 0 0 0 Other (please explain below) The answers depend on the end purpose of grouping and how many PFAS are grouped. If you would group all PFAS together then all the above categories would score 1 due to lack of information of the thousands of PFAS in use. If you take the PFAAs and perfluoroalkyl ether acids only, we know much more than for all PFAS, but are lacking toxicological data for some PFAAs and perfluoroalkyl ether acids. We also know little about production/use, properties and exposure for some perfluoroalkyl ether acids. Lack of information is often the reason for making precuationary simplifications in grouping approaches.
- Expert 7
Grouped by: 1 2 3 4 5 6 7 8 9 10 Production/Use Potential exposure route Biological half-life Physical-chemical properties Carbon chain length/chemical structure Toxicological endpoints Mode of action Other (please explain below) 0 0 0 0 0 0 0 0 0 1 They are all relevant but priorization needs to be undertaken and communicated before to proceed. And an organizational principle established for the report.
- Expert 2
Grouped by: 1 2 3 4 5 6 7 8 9 10 Production/Use 0 0 0 1 0 0 0 0 0 0 Potential exposure route 0 0 0 0 1 0 0 0 0 0 Biological half-life 0 0 0 0 0 1 0 0 0 0 Physical-chemical properties 0 0 0 0 1 0 0 0 0 0 Carbon chain length/chemical structure 0 0 0 0 1 0 0 0 0 0 Toxicological endpoints 0 0 0 0 0 1 0 0 0 0 Mode of action 0 0 0 0 0 0 0 1 0 0 Other (please explain below) Still we do not know much about physicochemical properties and it is not possible to group based on that.
- Expert 8
Grouped by: 1 2 3 4 5 6 7 8 9 10 Production/Use 0 0 0 0 0 0 0 0 0 1 Potential exposure route 0 0 0 0 0 0 0 0 0 1 Biological half-life 0 0 0 0 0 0 0 0 0 1 Physical-chemical properties 0 0 0 0 0 0 0 0 0 1 Carbon chain length/chemical structure 0 0 0 0 0 0 0 0 0 1 Toxicological endpoints 0 0 0 0 0 0 0 0 0 1 Mode of action 0 0 0 0 0 0 0 0 0 1 Other (please explain below) Again, there is no context to this question, and all are equally feasible depending on the specific scenario.
- Expert 6
Grouped by: 1 2 3 4 5 6 7 8 9 10 Production/Use 0 0 0 0 0 0 0 1 0 0 Potential exposure route 0 0 0 0 0 0 1 0 0 0 Biological half-life 0 0 0 1 0 0 0 0 0 0 Physical-chemical properties 0 0 0 0 0 1 0 0 0 0 Carbon chain length/chemical structure 0 0 0 0 0 0 0 0 1 0 Toxicological endpoints 0 0 1 0 0 0 0 0 0 0 Mode of action 0 1 0 0 0 0 0 0 0 0 Other (please explain below) See also answer to 1.3; the issue of "feasibility" changes the order of merit; with possibly insufficient information on toxicological profile and/or MoA across the spectrum of PFAS, a more pragmatic approach to grouping may be necessary
- Expert 3
Grouped by: 1 2 3 4 5 6 7 8 9 10 Production/Use 0 0 0 0 0 0 0 1 0 0 Potential exposure route 0 0 0 0 0 0 1 0 0 0 Biological half-life 0 0 0 0 0 1 0 0 0 0 Physical-chemical properties 0 0 0 0 0 0 0 1 0 0 Carbon chain length/chemical structure 0 0 0 0 0 0 0 1 0 0 Toxicological endpoints 0 0 0 0 1 0 0 0 0 0 Mode of action 0 0 0 0 1 0 0 0 0 0 Other (please explain below) Data are most abundant for those groups I ranked higher. Assuming that risk assessment strategies and research design are outcomes of this exercise, feasibility does not equal current availability of data. One can design (and in some cases require) studies that most contribute value to the information base.
- Expert 9
Grouped by: 1 2 3 4 5 6 7 8 9 10 Production/Use 0 1 0 0 0 0 0 0 0 0 Potential exposure route 0 1 0 0 0 0 0 0 0 0 Biological half-life 0 1 0 0 0 0 0 0 0 0 Physical-chemical properties 0 0 0 0 0 0 0 0 1 0 Carbon chain length/chemical structure 0 0 1 0 0 0 0 0 0 0 Toxicological endpoints 0 0 1 0 0 0 0 0 0 0 Mode of action 0 1 0 0 0 0 0 0 0 0 Other (please explain below) 0 0 0 0 0 0 0 0 1 0 Persistence. It is known that the vast majority of PFAS are persistent. Even those that are not, i.e., precursors, degrade to stable PFAS end products.
- Expert 11
Grouped by: 1 2 3 4 5 6 7 8 9 10 Production/Use 0 0 0 0 0 0 0 1 0 0 Potential exposure route 0 0 0 0 0 0 0 1 0 0 Biological half-life 0 0 0 0 0 0 0 1 0 0 Physical-chemical properties 0 0 0 0 0 0 0 1 0 0 Carbon chain length/chemical structure 0 0 0 0 0 0 0 0 0 1 Toxicological endpoints 0 0 1 0 0 0 0 0 0 0 Mode of action 1 0 0 0 0 0 0 0 0 0 Other (please explain below) The above numbers reflect my limited understanding of the availability of data for PFAS compounds that could be used for a grouping strategy and not the effectiveness of such a strategy.
- Expert 4
Grouped by: 1 2 3 4 5 6 7 8 9 10 Production/Use 0 0 0 0 0 0 0 0 0 1 Potential exposure route 0 0 0 0 0 1 0 0 0 0 Biological half-life 0 0 1 0 0 0 0 0 0 0 Physical-chemical properties 0 0 0 0 1 0 0 0 0 0 Carbon chain length/chemical structure 0 0 0 0 0 0 0 0 0 1 Toxicological endpoints 0 0 1 0 0 0 0 0 0 0 Mode of action 0 0 1 0 0 0 0 0 0 0 Other (please explain below) For most PFAS, there is scant information that would allow grouping by most of these criteria. That is why I gave low feasibility scores to half-life, toxicological endpoints and mode of action. There is a little more data on phys/chem properties. Potential exposure routes could be inferred based on production and use. Grouping by production and use or carbon chain length is the most feasible, since this information is most available.
- Expert 1
Grouped by: 1 2 3 4 5 6 7 8 9 10 Production/Use 0 0 0 1 0 0 0 0 0 0 Potential exposure route 0 0 0 1 0 0 0 0 0 0 Biological half-life 0 0 0 0 1 0 0 0 0 0 Physical-chemical properties 0 0 0 0 0 0 0 1 0 0 Carbon chain length/chemical structure 0 0 0 0 0 0 0 0 1 0 Toxicological endpoints 0 0 0 0 0 1 0 0 0 0 Mode of action 0 0 0 0 0 1 0 0 0 0 Other (please explain below) Given the number of past- and current-use PFAS and the lack of toxicological data on most of them, it seems like using chemical descriptors is the most realistic approach. However, as stated in other sections, grouping all the PFAS together would simplify and accelerate the process.
- Expert 5
Grouped by: 1 2 3 4 5 6 7 8 9 10 Production/Use 0 0 0 0 0 0 0 0 1 0 Potential exposure route 0 0 0 0 0 0 1 0 0 0 Biological half-life 0 0 0 0 0 1 0 0 0 0 Physical-chemical properties 0 0 0 0 0 0 0 1 0 0 Carbon chain length/chemical structure 0 0 0 0 0 0 0 0 0 1 Toxicological endpoints 0 0 0 0 1 0 0 0 0 0 Mode of action 0 1 0 0 0 0 0 0 0 0 Other (please explain below) Feasibility might be interpreted to mean the development of confidence in the determination, or it may mean strictly the ability to apply the specified data/characteristics to successfully group chemicals. Feasibility is here considered to represent “Can we group by “X”?”
The data most certain to be available might be chemical structure data; these data will be largely independent of chemical production, use, or biological endpoints. Next most available data might be production and use data. The numerical ratings applied here reflect this reviewer’s estimate of the likelihood of having or developing reliable data for each characteristic sufficient to serve as the basis for a credible grouping strategy. So, the toxicological endpoints and mode of action data may be the most reliable basis for chemical grouping to conduct a mixtures risk assessment for PFAS chemicals, but those data sets may also be the least likely to be available (for more than a few PFAS chemicals at present).
Expert 3
09/15/2021 13:47I did not agree with reviewer 1's comment that grouping all the PFAS together is the way to proceed. But when I got to discussion of screening approaches -- maybe that is the way to go. In my original comments on screening I suggested considering all PFAS to be equitoxic, assume additivity, and compare estimated exposure to a health benchmark.
Expert 3
09/15/2021 13:49Agree that production and use data are likely to be most available. Appreciate comments by reviewers that for screening could use these data with default assumptions for conservative estimate.
Expert 8
09/16/2021 13:43I think that the feasibility of each of these depends on the purpose and scope of the assessment. Risk assessment is an iterative process and some mey be initially feasible and others may become feasible over time. What is lacking, however, from this list as well as from all the questions, is exposure. Production is often used as a surrogate, but for some PFAS compounds there are actual measures of human exposure.
Expert 5
09/16/2021 14:30I relate best to answers provided by experts 1,4 and 6 - in that the data most likely to be available and undisputed may be chemical properties. Grouping to discriminate among chemicals might be best accomplished on the basis of factors that differ among groups, and so the use of persistence, as common to many, may induce complications, especially if potencies differ among chemicals with similar half-life values. Production and use data might be used to prioritize (but not necessarily group) chemicals for risk evaluation
Expert 7
09/20/2021 01:32I agree on Reviewer 1 first statement that "Given the number of past- and current-use PFAS and the lack of toxicological data on most of them, it seems like using chemical descriptors is the most realistic approach". However, I believe that in the view of the discussions before as to "PFAS" grouping together will only confuse and dilute the process. I prefer concrete examples.
I do not agree that production and use data are easy to access. There are historic data available but they do not match and newer "inventories" use past production numbers and processes. Further, amounts may only be available for regulated chemicals.
Finally, PFAS precursors are blamed for most of the occurrence (in monitoring exercises) and they cannot be covered by production/use amounts.
For any grouping, the source of information needs to be defined and accessible for verification.
Expert 10
09/22/2021 03:47Properties may be the most likely data available, but we be careful that we collect relevant properties given the unusual behaviour of PFAS, e.g. the octanol-water partition coefficient (Kow) is not relevant for fluorinated surfactant soprtion and bioaccumulation behavior. Also because of the unusual behaviour of PFAS, property estimation software often performs poorly.
Expert 4
09/23/2021 07:08I appreciated Expert 8's comment that feasibility of a particular approach can change over time, for example as new data becomes available. I also agreed with several experts that feasibility of any approach depends on the context of the risk assessment. In my mind feasibility is not just about whether the data is available. It is also about whether a useful result can be produced within an appropriate time frame and budget, and can inform risk management strategies if necessary.